14 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
million, compared with $3.5 million in the same period of the prior fiscal year. Research and Development (R&D) expense in the second quarter of fiscal 2024 … expenses were $6.9 million, compared with $6.8 million in the same period of fiscal 2023. R&D expense in the first six months of fiscal 2024 was $2.8
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
Technology Officer Prior to joining NeuroOne, Mr. Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
2024 were $3.7 million, compared with $3.2 million in the first quarter of fiscal 2023. R&D expense in the first quarter of fiscal 2024 was $1.5 million
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
period of the prior year. R&D expense in the fourth quarter of fiscal 2023 was $1.8 million compared with $1.4 million in the same period of fiscal … operating expenses for the full fiscal year 2023 were $13.9 million, compared with $11.9 million in the prior fiscal year. R&D expense for the full fiscal
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 Aug 23
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:15pm
with $2.8 million in the same period of the prior fiscal year. Research and Development (R&D) expense in the fiscal third quarter 2023 was $1.9 … million, compared with $8.6 million in the same period of the prior fiscal year. R&D expense in the first nine months of fiscal 2023 was $5.2 million
8-K
EX-99.1
9bw a9chdkl
11 May 23
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
2mpayi0oqlppg7
22 Dec 22
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
9:11am
8-K
EX-99.1
wga8ak5671tj3cj 0ltg
14 Sep 22
Regulation FD Disclosure
8:30am
8-K
EX-99.1
c1rrb674 cds
11 Aug 22
NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
4:49pm
8-K
EX-99.1
21zlyk3d
12 May 22
NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
4:17pm
8-K
EX-99.1
79shyhn
14 Feb 22
NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
iyks0csol6j6kzf
15 Dec 21
NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021
8:15am
8-K
EX-99.1
614j1 rn2g
13 Aug 21
NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update
8:05am
8-K
EX-99.1
od8i9n28c60
6 Apr 20
Regulation FD Disclosure
5:11pm
- Prev
- 1
- Next